Asarfi Hospital Ltd

Asarfi Hospital Ltd

₹ 198 3.26%
27 May 2:02 p.m.
About

Incorporated in 2005, Asarfi Hospital Ltd
provides primary health services & treatment
and specialized super speciality health service[1]

Key Points

Business Overview Asarfi Hospital Limited (AHL) operates three primary facilities:
a) Super Multi-Specialty Hospital (Baramuri, Dhanbad)[1]
- Structure and Capacity: This hospital spans four blocks and six floors, with a constructed area exceeding 100,000 square feet on 92 decimals of land. It houses 250 beds, with plans to expand capacity to 350 beds.
- Specializations: Cardiology and Neurology are major departments, generating nearly 50% of hospital revenue. Other key specialties include emergency care, general medicine, pediatrics, orthopedics, and obstetrics & gynecology.

b) Asarfi Cancer Institute (Ranguni, Dhanbad)[2]
- Location and Size: Built on 9.55 acres of leased land from the Jharkhand Industrial Area Development Authority (JIADA).
- Capacity and Occupancy: Currently, the Cancer Institute operates with 50 beds across two floors, achieving an average occupancy rate of 57% as of H1 FY25. Plans are underway to expand capacity to 150 beds with an additional investment of ₹2-3 crores.
- Unique Positioning: It is the only dedicated cancer hospital within a 200 km radius, offering specialized oncology services including medical, surgical, and radiation oncology.
- Future Expansion: The facility is approved for construction of up to seven floors, enabling substantial expansion.

c) Research Institute (Ranchi)[3]
- Location and Infrastructure: Located 4 km from Ranchi Airport, in proximity to HEC India, on 5.6 acres of acquired land for 13.5 Crs
- Development Plans: AHL plans to establish medical and non-medical research management courses by FY28. The land’s value has appreciated since its acquisition, estimated at ₹65 crores.

  • Market Cap 390 Cr.
  • Current Price 198
  • High / Low 257 / 115
  • Stock P/E 23.4
  • Book Value 49.6
  • Dividend Yield 0.00 %
  • ROCE 18.6 %
  • ROE 18.6 %
  • Face Value 10.0

Pros

  • Company is expected to give good quarter
  • Company's working capital requirements have reduced from 24.2 days to 19.3 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 13.2% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
20.05 24.04 22.92 30.86 32.89 35.10 35.68 44.89 46.10 45.24
16.04 20.10 18.16 24.10 25.93 28.81 28.69 36.02 36.00 37.51
Operating Profit 4.01 3.94 4.76 6.76 6.96 6.29 6.99 8.87 10.10 7.73
OPM % 20.00% 16.39% 20.77% 21.91% 21.16% 17.92% 19.59% 19.76% 21.91% 17.09%
1.20 -0.41 0.68 1.13 0.89 3.61 1.42 0.76 1.48 0.64
Interest 0.60 0.76 0.80 0.76 1.18 1.35 1.22 1.07 1.25 0.71
Depreciation 3.25 3.49 3.18 3.19 3.05 3.25 2.99 2.91 2.88 2.76
Profit before tax 1.36 -0.72 1.46 3.94 3.62 5.30 4.20 5.65 7.45 4.90
Tax % 102.94% -70.83% 0.00% 27.41% 25.69% 32.26% 25.71% 25.66% 27.25% 20.20%
-0.05 -0.21 1.45 2.85 2.68 3.59 3.12 4.20 5.42 3.92
EPS in Rs -0.03 -0.11 0.74 1.45 1.36 1.82 1.59 2.13 2.75 1.99
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
81 116 174
65 93 138
Operating Profit 16 24 35
OPM % 20% 20% 20%
2 8 3
Interest 3 4 4
Depreciation 9 13 12
Profit before tax 6 14 22
Tax % 33% 26% 25%
4 11 17
EPS in Rs 2.11 5.38 8.47
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 49%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 62%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 59%
Return on Equity
10 Years: %
5 Years: %
3 Years: 13%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 20 20 20
Reserves 51 61 78
32 49 58
52 34 38
Total Liabilities 154 164 193
94 102 108
CWIP 0 2 2
Investments 0 0 0
60 60 83
Total Assets 154 164 193

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
26 -4 18
-63 -7 -18
36 13 5
Net Cash Flow -1 1 5
Free Cash Flow -20 -15 0
CFO/OP 163% -5% 68%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 109 125 114
Inventory Days 32 30 30
Days Payable 447 171 156
Cash Conversion Cycle -305 -16 -12
Working Capital Days 3 50 19
ROCE % 16% 19%

Insights

In beta
Mar 2014 Mar 2016 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Bed Capacity
Number of beds ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
In-patient (IPD) Volume
Number of patients ・Standalone data
Out-patient (OPD) Volume
Number of patients ・Standalone data
Super-Specialty ARPOB
INR ・Standalone data
Super-Specialty Hospital Bed Occupancy Rate
% ・Standalone data
Total Medical Professionals (Doctors)
Number ・Standalone data
Cancer Hospital ARPOB
INR ・Standalone data
Cancer Hospital Average Length of Stay (ALOS)
Days ・Standalone data
Cancer Hospital Bed Occupancy Rate
% ・Standalone data
Nursing and Support Staff
Number ・Standalone data
Super-Specialty Average Length of Stay (ALOS)
Days ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
61.17% 61.17% 61.17% 61.17% 61.17% 61.17% 61.17% 61.17%
0.00% 0.00% 0.00% 0.00% 0.10% 0.05% 0.00% 0.00%
3.26% 2.33% 1.95% 2.92% 3.19% 2.18% 1.98% 2.40%
35.58% 36.50% 36.89% 35.92% 35.55% 36.59% 36.86% 36.44%
No. of Shareholders 7061,2611,2841,2621,1761,1671,2251,316

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls